OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
Jianyang Liu, Qunying Mao, Xing Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Jianyang Liu, Qunying Mao, Xing Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Showing 14 citing articles:
Research progress on circular RNA vaccines
Yu Bai, Dong Liu, Qian He, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 32
Yu Bai, Dong Liu, Qian He, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 32
Two-year follow-up of the COVID-19 pandemic in Mexico
Antonio Loza, Rosa María Wong‐Chew, María Eugenia Jiménez-Corona, et al.
Frontiers in Public Health (2023) Vol. 10
Open Access | Times Cited: 19
Antonio Loza, Rosa María Wong‐Chew, María Eugenia Jiménez-Corona, et al.
Frontiers in Public Health (2023) Vol. 10
Open Access | Times Cited: 19
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review
Yeqing Sun, Weijin Huang, Hongyu Xiang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 554-554
Open Access | Times Cited: 5
Yeqing Sun, Weijin Huang, Hongyu Xiang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 554-554
Open Access | Times Cited: 5
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine
Bruno Vinícius Santos Valiate, Julia Castro, Tomás Gazzinelli Marçal, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110177-110177
Open Access | Times Cited: 2
Bruno Vinícius Santos Valiate, Julia Castro, Tomás Gazzinelli Marçal, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110177-110177
Open Access | Times Cited: 2
SARS‐CoV‐2 evolves to reduce but not abolish neutralizing action
Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Xiaosong Lin, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 11
Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Xiaosong Lin, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 11
Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
Lidong Guan, Qunying Mao, Dejiang Tan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Lidong Guan, Qunying Mao, Dejiang Tan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison
Fernando Alcorta-Núñez, Diana Cristina Pérez-Ibave, Carlos Horacio Burciaga-Flores, et al.
Diagnostics (2023) Vol. 13, Iss. 6, pp. 1194-1194
Open Access | Times Cited: 5
Fernando Alcorta-Núñez, Diana Cristina Pérez-Ibave, Carlos Horacio Burciaga-Flores, et al.
Diagnostics (2023) Vol. 13, Iss. 6, pp. 1194-1194
Open Access | Times Cited: 5
Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants
Xuanxuan Zhang, Lidong Guan, Na Li, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 554-554
Open Access | Times Cited: 1
Xuanxuan Zhang, Lidong Guan, Na Li, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 554-554
Open Access | Times Cited: 1
Rapid Quantification of SARS-CoV-2 Neutralising Antibodies Using Time-Resolved Fluorescence Immunoassay
Gary R. McLean, Yueke Zhang, Rene Ndoyi, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2149-2149
Open Access | Times Cited: 7
Gary R. McLean, Yueke Zhang, Rene Ndoyi, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2149-2149
Open Access | Times Cited: 7
Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies
Javeria Aijaz, Fatima Kanani, Fouzia Naseer
Journal of Clinical Virology Plus (2023) Vol. 3, Iss. 1, pp. 100137-100137
Open Access | Times Cited: 3
Javeria Aijaz, Fatima Kanani, Fouzia Naseer
Journal of Clinical Virology Plus (2023) Vol. 3, Iss. 1, pp. 100137-100137
Open Access | Times Cited: 3
Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept
Jianyang Liu, Yu Bai, Mingchen Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Jianyang Liu, Yu Bai, Mingchen Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Assessment of Antibody Titers after 6 Months of Vaccination against SARS-COV-2 in Patients with CKD Stage 4, 5 and CKD 5d
Dr. Md Farucul Hasan, Prof. Dr. Md. Nazrul Islam, Abu Saleh Ahmed, et al.
Saudi Journal of Medical and Pharmaceutical Sciences (2024) Vol. 10, Iss. 07, pp. 436-446
Open Access
Dr. Md Farucul Hasan, Prof. Dr. Md. Nazrul Islam, Abu Saleh Ahmed, et al.
Saudi Journal of Medical and Pharmaceutical Sciences (2024) Vol. 10, Iss. 07, pp. 436-446
Open Access
Immunogenicity and safety of CoronaVac in children in an immuno-bridging phase 3 clinical trial
Weining Meng, Qin Sun, Ying Xie, et al.
Research Square (Research Square) (2023)
Open Access
Weining Meng, Qin Sun, Ying Xie, et al.
Research Square (Research Square) (2023)
Open Access
